Chemclin Diagnostics(SH:688468) Sou Hu Cai Jing·2025-07-18 11:23Core Viewpoint - The company, Kemei Diagnostics, has shown a decline in revenue and net profit in the latest quarterly report, while its stock price has reached a new low in terms of rolling P/E ratio compared to the industry average [1][2]. Company Summary - Kemei Diagnostics closed at 7.73 yuan, up 2.11%, with a rolling P/E ratio of 30.04, marking a 77-day low and a total market capitalization of 3.101 billion yuan [1]. - The company operates in the clinical immunochemistry and chemiluminescence diagnostic testing sector, focusing on the research, production, and sales of diagnostic reagents and instruments [1]. - The main products include the LiCA series and CC series [1]. - In the reporting period, Kemei Diagnostics obtained 64 new domestic and international patents, including 33 domestic invention patents, 20 utility model patents, and 11 design patents, indicating strong innovation capability and technical reserves [1]. Financial Performance - For Q1 2025, Kemei Diagnostics reported revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]. Industry Summary - The average P/E ratio for the medical device industry is 52.34, with a median of 36.99, placing Kemei Diagnostics at the 64th position within the industry [2]. - The average P/B ratio for the industry is 4.60, while Kemei Diagnostics has a P/B ratio of 2.17 [2]. - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].